✓
Open
5 Jun 2026
✓
Close
9 Jun 2026
3
Allotment
—
✓
Listing
Fri, Jun 12, 2026
Price Band
₹42 to ₹45
Issue Size
3,08,59,704 shares (agg. up to ₹139 Cr)
Lot Size
333 Shares
Listing Date
Fri, Jun 12, 2026
Latest GMP
₹2.75
Est. Gain
6.11%
✦ AI Insight
GMP Trend
12-06-2026₹2.75Est. ₹47.75+6.11%
11-06-2026₹2.75Est. ₹47.75+6.11%
10-06-2026₹2.75Est. ₹47.75+6.11%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 37.47x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 327.60 | 261.36 | 250.54 | 288.90 |
| Total Income | 275.57 | 331.29 | 304.62 | 281.65 |
| Profit After Tax | 27.03 | 24.38 | 12.21 | 5.82 |
| EBITDA | 37.55 | 40.07 | 24.88 | 17.17 |
| NET Worth | 223.05 | 195.60 | 176.29 | 163.84 |
| Reserves and Surplus | 210.92 | 183.89 | 164.51 | 152.30 |
| Total Borrowing | 39.79 | 26.60 | 36.89 | 51.87 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹570.70 (+1.02%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,064.90 (+0.13%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,419.00 (-3.11%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹165.27 (-1.98%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.18 (+0.53%) |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹135.00 (-1.39%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹39.05 (+0.08%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹178.60 (+0.17%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹262.00 (-0.70%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹242.70 (-0.98%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹105.05 (+2.79%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹249.35 (+2.66%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹73.50 (-2.00%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹290.00 (-0.60%) |
About Hexagon Nutrition IPO
Incorporated in 1993, Hexagon Nutrition Ltd. is a research-driven nutrition company. It is engaged in developing and manufacturing products across micronutrient premixes, branded wellness and clinical nutrition, therapeutic formulations, and ready-to-use foods. The company operates three manufacturing facilities in India, located at Nasik (Maharashtra), Chennai (Tamil Nadu), and Thoothukudi (Tamil Nadu), along with an international unit in Tashkent, Uzbekistan. Two Indian facilities are situated in SEZ zones at Chennai and Thoothukudi, providing strategic advantages such as proximity to ports and duty-free imports. Its product portfolio is classified into three segments: Branded wellness and clinical nutrition products (B2C) Premix formulations (B2B2C) Ready-to-Use Foods (RUFs) and Micronutrient Powders (MNPs) under ESG initiatives Hexagon Nutrition has a PAN-India omnichannel distribution network covering retail pharmacies, hospital networks, e-commerce platforms, online pharmacies, and its own branded websites including Pentasure, Obesigo, Pediagold, and Nutrone. For domestic distribution, it works with over 358 distributors across India, including 8 with multi-state presence. Th
Contact Details
Hexagon Nutrition Ltd. Address404 Global ChamberAdarsh Nagar Link RoadAndheri (West)Mumbai, Maharashtra, 400053+91 22 6213 6710cs.hnpl@hexagonnutrition.comVisit Website